Those amazing results for Allocetra are false. In the PR for the phase 1 results they describe the patients as severe. The exclusion criteria excludes severe and even high moderate. In the phase 2 trial it is described as severe/critical, yet once again it's moderate.That all 12 of patients with middle of the road moderate or better survived is no great surprise.